Topic: Sanofi-Aventis SA
PARIS (Reuters) - French drugmaker Sanofi said a late-stage study of its lixisenatide drug in combination with Lantus insulin showed a significant improvement in blood sugar levels and a beneficial effect on body weight in type 2 diabetes patients.Lixisenatide, which will be ...
India is facing a twin epidemic of diabetes and high blood pressure, doctors have warned, after the results of a countrywide study suggested that one in five people had both conditions.The two-year study of nearly 16,000 adults in eight states found that ...
SAN DIEGO (Reuters) - Obesity and longevity have helped make diabetes an epidemic in much of the world, and drugmakers are jockeying to make sure their medicines are used early and often.Companies including Sanofi and Eli Lilly aim to introduce new classes ...
SAN DIEGO (Reuters) - A trial of Sanofi's experimental once-daily drug for Type 2 diabetes, Lyxumia, found that it worked as well as Byetta, a similar drug sold by Amylin and Eli Lilly and Co that is injected twice a day.The six-month ...
LONDON/SAN DIEGO (Reuters) - The number of adults with diabetes worldwide has more than doubled since 1980 to 347 million, a far larger number than previously thought and one that suggests costs of treating the disease will also balloon.In a study published ...
PARIS (Reuters) - Sanofi's candidate drug Lyxumia, or lixisenatide, added to basal insulin, significantly reduced blood sugar levels in type 2 diabetes patients and also led to a loss in weight, data published on Tuesday showed.Lyxumia belongs to the GLP-1 class of ...
NVO) said it will commit up to $100 million to expand its Beijing R&D center. Novo Nordisk says the growth will make its center the largest wholly-owned foreign R&D operation in China. The first multinational pharma to open a China R&D facility, ...
PARIS (Reuters) - Sanofi-Aventis , which is seeking to buy U.S. biotech firm Genzyme to boost its drug portfolio, signed a major R&D outsourcing deal with Covance on Thursday in an attempt to improve returns.The U.S. contract research group, which will become ...
Last week, Sanofi-Aventis (SNY) confirmed that it is on the prowl for diabetes partnerships. may consider candidates for a successor to its best-selling product, the long-acting insulin Lantus, and for a new, fast-acting insulin. Herein lies the problem: diabetics trying to time ...
Sanofi-Aventis reports positive blood sugar control for experimental diabetes drugSanofi-Aventis said Monday that a study of its experimental diabetes drug showed better blood sugar control than placebo.The study included 361 patients with type 2 diabetes who randomly received either lixisenatide, the company's ...
From Around the Web
Video Gallery
-
Mergers & Acquisitions: Sanofi-Aventis SA Bids $18...
"Sanofi-Aventis (NYSE:SNY) making a hostile $18.5 billion bid ...2010-10-04 -
Sanofi-Aventis Seeking Suitor For US Dermatology ...
Sanofi-Aventis SA (NYSE:SNY), France's largest drug maker, is ...2011-04-14 -
SRS (SA) 2009 Sanofi-Aventis Prize Winner
Dr David Muchuweti Abdominal Surgical Site Infection: Risk factors and ...2010-02-04
